Published in Kidney Int on July 01, 2003
Laboratory markers of ventricular arrhythmia risk in renal failure. Biomed Res Int (2014) 0.77
Electrocardiogram with prolonged QT interval in Gitelman disease. Kidney Int (2002) 2.32
A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol (2006) 3.74
Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients. J Am Soc Nephrol (2008) 1.75
Aldosterone and refractory hypertension: a prospective cohort study. Am J Hypertens (2006) 1.53
Renal vein renin measurements accurately identify renovascular hypertension caused by total occlusion of the renal artery. J Hypertens (2002) 1.48
Downregulation of the longevity-associated protein sirtuin 1 in insulin resistance and metabolic syndrome: potential biochemical mechanisms. Diabetes (2010) 1.48
Rosiglitazone reduces glucose-induced oxidative stress mediated by NAD(P)H oxidase via AMPK-dependent mechanism. Arterioscler Thromb Vasc Biol (2007) 1.44
Abnormal regulation of G protein alpha(i2) subunit in skin fibroblasts from insulin-resistant hypertensive individuals. J Hypertens (2004) 1.42
Antioxidant effect of L-carnitine and its short chain esters: relevance for the protection from oxidative stress related cardiovascular damage. Int J Cardiol (2006) 1.30
Reduced expression of regulator of G-protein signaling 2 (RGS2) in hypertensive patients increases calcium mobilization and ERK1/2 phosphorylation induced by angiotensin II. J Hypertens (2006) 1.20
The role of oxidized low-density lipoproteins in atherosclerosis: the myths and the facts. Mediators Inflamm (2013) 1.15
Intravenous thrombolysis with rt-PA in acute ischemic stroke patients aged older than 80 years in Italy. Cerebrovasc Dis (2007) 1.12
Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension (2002) 1.08
Angiotensin II type 1 and type 2 receptor interplay in hypertension: lesson from a human model of vascular hyporeactivity. J Hypertens (2013) 1.07
Metformin prevents glucose-induced protein kinase C-beta2 activation in human umbilical vein endothelial cells through an antioxidant mechanism. Diabetes (2005) 1.05
In-hospital percentage BNP reduction is highly predictive for adverse events in patients admitted for acute heart failure: the Italian RED Study. Crit Care (2010) 1.04
Interplay between miR-155, AT1R A1166C polymorphism, and AT1R expression in young untreated hypertensives. Am J Hypertens (2010) 1.02
Callipeltin A: sodium ionophore effect and tension development in vascular smooth muscle. Biochem Pharmacol (2004) 0.99
Angiotensin II-stimulated collagen production in cardiac fibroblasts is mediated by reactive oxygen species. J Hypertens (2006) 0.99
Mild hyperparathyroidism: a novel surgically correctable feature of primary aldosteronism. J Hypertens (2012) 0.98
Diabetic cardiomyopathy: a metabolic perspective. Am J Cardiol (2004) 0.97
Phosphate binders and management of hyperphosphataemia in end-stage renal disease. Nephrol Dial Transplant (2006) 0.97
Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma. J Hypertens (2007) 0.96
Aortic valve replacement in severe aortic stenosis with left ventricular dysfunction: determinants of cardiac mortality and ventricular function recovery. Eur J Cardiothorac Surg (2003) 0.94
Vitamin C prevents zidovudine-induced NAD(P)H oxidase activation and hypertension in the rat. Cardiovasc Res (2006) 0.90
Hyperparathyroidism can be useful in the identification of primary aldosteronism due to aldosterone-producing adenoma. Hypertension (2012) 0.89
Effects of angiotensin II and insulin on ERK1/2 activation in fibroblasts from hypertensive patients. Am J Hypertens (2004) 0.89
Increased expression of regulator of G protein signaling-2 (RGS-2) in Bartter's/Gitelman's syndrome. A role in the control of vascular tone and implication for hypertension. J Clin Endocrinol Metab (2004) 0.89
An abnormal gene expression of the beta-adrenergic system contributes to the pathogenesis of cardiomyopathy in cirrhotic rats. Hepatology (2008) 0.88
Urine therapy through the centuries. J Nephrol (2011) 0.88
Insulin generates free radicals by an NAD(P)H, phosphatidylinositol 3'-kinase-dependent mechanism in human skin fibroblasts ex vivo. Diabetes (2004) 0.88
Ultrafiltration in heart failure with cardiorenal syndrome. N Engl J Med (2013) 0.87
G-protein beta3-subunit gene 825T allele and hypertension: a longitudinal study in young grade I hypertensives. Hypertension (2003) 0.87
Phosphate salivary secretion in hemodialysis patients: implications for the treatment of hyperphosphatemia. Nephron Physiol (2007) 0.86
Angiotensin II type 1 receptor gene polymorphism predicts development of hypertension and metabolic syndrome. Am J Hypertens (2008) 0.86
Oxidative stress in kidney transplant patients with calcineurin inhibitor-induced hypertension: effect of ramipril. J Cardiovasc Pharmacol (2002) 0.83
Reduced content of alpha subunit of Gq protein content in monocytes of Bartter and Gitelman syndromes: relationship with vascular hyporeactivity. Kidney Int (2002) 0.83
Insulin generates free radicals in human fibroblasts ex vivo by a protein kinase C-dependent mechanism, which is inhibited by pravastatin. Free Radic Biol Med (2006) 0.82
SIRT1, heme oxygenase-1 and NO-mediated vasodilation in a human model of endogenous angiotensin II type 1 receptor antagonism: implications for hypertension. Hypertens Res (2013) 0.82
Oxidation of Met1606 in von Willebrand factor is a risk factor for thrombotic and septic complications in chronic renal failure. Biochem J (2012) 0.81
RGS2 expression and aldosterone: renin ratio modulate response to drug therapy in hypertensive patients. J Hypertens (2010) 0.81
Nifedipine versus carvedilol in the treatment of de novo arterial hypertension after liver transplantation: results of a controlled clinical trial. Liver Transpl (2008) 0.81
Silencing regulator of G protein signaling-2 (RGS-2) increases angiotensin II signaling: insights into hypertension from findings in Bartter's/Gitelman's syndromes. J Hypertens (2008) 0.81
Salivary glands: a new player in phosphorus metabolism. J Ren Nutr (2011) 0.81
Systolic and diastolic short-term blood pressure variability and its determinants in patients with controlled and uncontrolled hypertension: a retrospective cohort study. Blood Press (2015) 0.81
Genome-wide association study identifies CAMKID variants involved in blood pressure response to losartan: the SOPHIA study. Pharmacogenomics (2014) 0.81
Does p63RhoGEF, a new key mediator of angiotensin II signalling, play a role in blood pressure regulation and cardiovascular remodelling in humans? J Renin Angiotensin Aldosterone Syst (2011) 0.80
Angiotensin II-induced over-activation of p47phox in fibroblasts from hypertensives: which role in the enhanced ERK1/2 responsiveness to angiotensin II? J Hypertens (2005) 0.80
The search for a link between inflammation and hypertension--contribution from Bartter's/Gitelman's syndromes. Nephrol Dial Transplant (2006) 0.79
Pseudohyperaldosteronism: pathogenetic mechanisms. Crit Rev Clin Lab Sci (2003) 0.79
Phosphate content of beverages in addition to food phosphate additives: real and insidious danger for renal patients. J Ren Nutr (2011) 0.79
Long-term proton pump inhibitor use is associated with vascular calcification in chronic kidney disease: a cross-sectional study using propensity score analysis. Drug Saf (2013) 0.79
Aldosterone, inflammation, and preeclampsia. Hypertension (2005) 0.79
Rho/Rho-kinase and C-reactive protein relationship in hypertension and atherosclerosis. Nephrol Dial Transplant (2005) 0.79
Reduced mRNA and protein content of rho guanine nucleotide exchange factor (RhoGEF) in Bartter's and Gitelman's syndromes: relevance for the pathophysiology of hypertension. Am J Hypertens (2005) 0.79
Antioxidant and antiinflammatory effect of carvedilol in mononuclear cells of hypertensive patients. Am J Med (2005) 0.79
Outcome after acute ischemic stroke (AIS) in older patients: effects of age, neurological deficit severity and blood pressure (BP) variations. Arch Gerontol Geriatr (2010) 0.78
RGS2 C1114G polymorphism and body weight gain in hypertensive patients. Metabolism (2008) 0.78
High phosphate content beverages in dialysis patients: relevance for hyperphosphatemia and cardiovascular risk. Nutr Metab Cardiovasc Dis (2008) 0.78
Early markers of inflammation in a high angiotensin II state--results of studies in Bartter's/Gitelman's syndromes. Nephrol Dial Transplant (2006) 0.78
Miscellaneous non-inflammatory musculoskeletal conditions. Bartter's and Gitelman's diseases. Best Pract Res Clin Rheumatol (2011) 0.77
High-altitude cerebral effects: risks and mechanisms. Lancet Neurol (2009) 0.77
Mononuclear leukocyte mineralocorticoid receptors. A possible link between aldosterone and atherosclerosis. Hypertension (2006) 0.77
The Li+/Na+ exchange in hypertension. Front Biosci (2003) 0.77
Association of serum phosphorus concentration with cardiovascular risk. Am J Kidney Dis (2009) 0.77
Rho kinase and PAI-1 in Bartter's/Gitelman's syndromes: relationship to angiotensin II signaling. J Hypertens (2004) 0.77
L-carnitine, inflammation and hypertension. Nephrology (Carlton) (2009) 0.77
Specific effect of arachidonic acid on inducible nitric oxide synthase mRNA expression in human osteoblastic cells. Clin Sci (Lond) (2005) 0.76
Blood pressure in acute ischemic stroke and mortality: a study with noninvasive blood pressure monitoring. Blood Press Monit (2006) 0.76
Apparent mineralcorticoid excess syndrome, an often forgotten or unrecognized cause of hypokalemia and hypertension: case report and appraisal of the pathophysiology. Blood Press (2013) 0.76
Autonomic nervous system function in chronic hypotension associated with Bartter and Gitelman syndromes. Am J Kidney Dis (2007) 0.76
Treatment with calcimimetic (cinacalcet) alters epoetin dosage requirements in dialysis patients: preliminary report. Ren Fail (2011) 0.76
NADPH oxidase subunits (NOX-1, p22phox, Rac-1) and tacrolimus-induced nephrotoxicity in a rat renal transplant model. Nephrol Dial Transplant (2007) 0.76
An update on hypertensive emergencies and urgencies. J Cardiovasc Med (Hagerstown) (2015) 0.76
Salivary phosphorus and phosphate content of beverages: implications for the treatment of uremic hyperphosphatemia. J Ren Nutr (2009) 0.76
Oxidative stress-related factors in Bartter's and Gitelman's syndromes: relevance for angiotensin II signalling. Nephrol Dial Transplant (2003) 0.76
Kidney transplant in Gitelman's syndrome. Report of the first case. J Nephrol (2003) 0.76
Salivary glands: a 'third kidney' for phosphate excretion in kidney disease? Blood Purif (2009) 0.76
Galphai2 expression, hypertension and insulin resistance. J Hypertens (2006) 0.75
Number and function of circulating endothelial progenitor cells and calcitonin gene-related peptide in hypertension: support from and opportunities in Bartter's and Gitelman's syndromes patients. J Hypertens (2010) 0.75
Rho kinase inhibition and vascular protection: support from studies in Bartter and Gitelman syndrome. Arterioscler Thromb Vasc Biol (2005) 0.75
NADPH oxidase, superoxide overproduction and nitric oxide bioavailability in essential hypertension. J Hypertens (2005) 0.75
L-carnitine and erythropoiesis: relationship with haeme oxygenase-1. Nephrol Dial Transplant (2005) 0.75
HO-1 attenuates hypertension-induced inflammation/oxidative stress: support from Bartter's/Gitelman's patients. Am J Hypertens (2010) 0.75
The PGC1alpha-PPARdelta-HO-1 system: supporting evidence from studies in Bartter's/Gitelman's syndromes. Cardiovasc Res (2010) 0.75
Carnitine'S protective effect on oxidative stress is mediated by heme oxygenase-1. Nephrology (Carlton) (2006) 0.75
Antihypertensive treatment and cognitive function: another tempest in a P pot? J Hypertens (2008) 0.75
Aldosterone-mediated endothelial remodeling and oxidative stress. Kidney Int (2005) 0.75
'The heart never grows better by ''AGE''; i fear rather worse...'. Philip Stanhope, 4th Earl of Chesterfield. Blood Purif (2006) 0.75
EPO induces rise in serum ADMA but does not prevent the increase in NO release: the likely involvement of HO-1. Nephrol Dial Transplant (2008) 0.75